EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dextromethorphan Enhances Apoptosis and Suppresses EMT in PANC-1 Pancreatic Cancer Cells: Synergistic Effects with Gemcitabine

Gulsah Medet, Ahmet Inal iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26178151 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Gulsah Medet und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Institute of Health Sciences, Erciyes University, Kayseri 38039, Turkey. Hauptthemen laut MEDLINE: Epithelial-Mesenchymal Transition, Deoxycytidine, Apoptosis, Pancreatic Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Erciyes University Scientific Research Projects Unit.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to evaluate the effects of dextromethorphan (DX), alone and in combination with gemcitabine (GEM), on cell viability, apoptosis, and epithelial–mesenchymal transition (EMT) markers in PANC-1 human pancreatic cancer cells. PANC-1 human pancreatic cancer cells were cultured and treated with varying concentrations of dextromethorphan (DX), gemcitabine (GEM), and 5-fluorouracil (5-FU), both as monotherapies and in combination. Cytotoxic effects were assessed using the MTT assay, and IC50 values were calculated at 24, 48, and 72 h. Apoptotic responses were evaluated using Annexin V-FITC/PI staining followed by flow cytometry. Protein expression levels of Bax, Bcl-2, and Vimentin were determined via immunocytochemistry, while EMT markers (E-cadherin, N-cadherin, Vimentin) were analyzed using flow cytometry. Relative mRNA expression of apoptotic and EMT-related genes was quantified by qRT-PCR. DX exhibited time- and dose-dependent cytotoxicity in PANC-1 cells, with IC50 values of 280.4 µM at 24 h, 163.2 µM at 48 h, and 105.6 µM at 72 h. For GEM, the 72 h IC50 was 57.53 µM. The combination of DX 50 µM + GEM 12.5 µM resulted in significantly lower cell viability (24.93 ± 3.12%) compared to GEM 25 µM (35.33 ± 5.22%) and DX 100 µM (51.40 ± 3.10%) (p < 0.001). Flow cytometry revealed significant increases in early (21.83 ± 1.32%) and late apoptotic cells (32.20 ± 0.84%) in the combination group, with a corresponding reduction in viable cells compared to control (24.93 ± 3.12% vs. 89.53 ± 0.97%, p < 0.001). Immunocytochemical analysis showed increased Bax-positive cell count (62.0 cells/unit area), and decreased Bcl-2 (19.0) and Vimentin (28.0) levels in the combination group compared to control (Bax: 15.0, Bcl-2: 60.0, Vimentin: 70.0) (p < 0.001). Flow cytometry for EMT markers demonstrated increased E-cadherin (83.84 ± 0.65%) and decreased Vimentin (71.04 ± 1.17%) and N-cadherin (30.47 ± 0.72%) expression in the DX + GEM group compared to EMT control (E-cadherin: 68.97 ± 1.43%, Vimentin: 91.00 ± 0.75%, N-cadherin: 62.47 ± 1.13%) (p < 0.001). qRT-PCR supported these findings with increased Bax (2.1-fold), E-cadherin (2.0-fold), and reduced Bcl-2 (0.3-fold) and XIAP (0.6-fold) in the combination group (p < 0.05). Dextromethorphan, particularly in combination with gemcitabine, appears to enhance apoptosis and suppress EMT-associated marker expression in PANC-1 cells, supporting its potential as an adjuvant agent in pancreatic cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epithelial-Mesenchymal TransitionDeoxycytidineApoptosisPancreatic NeoplasmsDextromethorphanHumansGemcitabineDrug SynergismCell Line, TumorCell SurvivalGene Expression Regulation, NeoplasticVimentinFluorouracil

Stichwörter der Autor:innen

EMTNMDA receptor antagonistPANC-1apoptosisdextromethorphanpancreatic cancer

Substanzen

GemcitabineDeoxycytidineDextromethorphanVimentinFluorouracil

Autor:innen und Institutionen

  • Department of Pharmacology, Institute of Health Sciences, Erciyes University, Kayseri 38039, Turkey.
  • Department of Pharmacology, School of Medicine, Erciyes University, Kayseri 38039, Turkey.

ORCID-Profile: Ahmet Inal

Förderung

  • Erciyes University Scientific Research Projects Unit

Zitieren

APA

Medet, G., & Inal, A. (2025). Dextromethorphan Enhances Apoptosis and Suppresses EMT in PANC-1 Pancreatic Cancer Cells: Synergistic Effects with Gemcitabine. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26178151

Vancouver

Medet G, Inal A. Dextromethorphan Enhances Apoptosis and Suppresses EMT in PANC-1 Pancreatic Cancer Cells: Synergistic Effects with Gemcitabine. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26178151

BibTeX
@article{Medet2025,
  author = {Medet, Gulsah and Inal, Ahmet},
  title = {Dextromethorphan Enhances Apoptosis and Suppresses EMT in PANC-1 Pancreatic Cancer Cells: Synergistic Effects with Gemcitabine},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26178151}
}
Kostenlos starten →